Ignite Creation Date:
2025-12-24 @ 7:07 PM
Ignite Modification Date:
2026-01-29 @ 12:06 PM
Study NCT ID:
NCT02959957
Status:
COMPLETED
Last Update Posted:
2019-09-16
First Post:
2016-10-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'submissionInfos': [{'resetDate': '2021-06-04', 'releaseDate': '2021-05-11'}], 'estimatedResultsFirstSubmitDate': '2021-05-11'}}, 'conditionBrowseModule': {'meshes': [{'id': 'D014552', 'term': 'Urinary Tract Infections'}], 'ancestors': [{'id': 'D007239', 'term': 'Infections'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C031367', 'term': 'temocillin'}, {'id': 'D002439', 'term': 'Cefotaxime'}], 'ancestors': [{'id': 'D002505', 'term': 'Cephacetrile'}, {'id': 'D002511', 'term': 'Cephalosporins'}, {'id': 'D047090', 'term': 'beta-Lactams'}, {'id': 'D007769', 'term': 'Lactams'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D013843', 'term': 'Thiazines'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 157}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-05-20', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-09', 'completionDateStruct': {'date': '2019-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-09-12', 'studyFirstSubmitDate': '2016-10-13', 'studyFirstSubmitQcDate': '2016-11-07', 'lastUpdatePostDateStruct': {'date': '2019-09-16', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-11-09', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2019-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Frequency of adverse events', 'timeFrame': 'From the first dose of study drug until 4-6 weeks after discontinuation of antibiotic treatment (parenteral and per oral).'}], 'primaryOutcomes': [{'measure': 'Number of patients with emergence of any of the two following events: Colonisation or infection with C. difficile and/or with Enterobacteriaceae resistant to 3rd generation cephalosporins. Measured in cultures from faecal samples.', 'timeFrame': 'Within 12 hours after the last dose of study drug.', 'description': 'Superiority analysis.'}], 'secondaryOutcomes': [{'measure': 'Number of patients with clinical cure in each treatment group.', 'timeFrame': '7-10 days after discontinuation of antibiotic treatment (parenteral and oral).', 'description': 'Clinical cure defined as patient totally recovered with no remaining symptoms of UTI or no recurrence with symptoms or no need of further treatment against the current infection. Non-inferiority analysis.'}, {'measure': 'Number of patients with early clinical response.', 'timeFrame': 'Within 12 hours after the 9th dose of study drug.', 'description': 'Non-inferiority analysis.'}, {'measure': 'Bacteriological cure per patient and per pathogen measured as negative urine Culture <1000 CFU/ml.', 'timeFrame': '7-10 days after discontinuation of antibiotic treatment (parenteral and oral).', 'description': 'Non-inferiority analysis.'}, {'measure': 'Early bacteriological response measured as negative urine Culture <1000 CFU/ml.', 'timeFrame': 'Within 12 hours after the 9th dose of study drug.', 'description': 'Non-inferiority analysis.'}, {'measure': 'Rate of patients with diarrhea (≥ 3 loose stools per day)', 'timeFrame': 'From the first dose of study drug until 7-10 days after discontinuation of antibiotic treatment (parenteral and oral).'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Urinary Tract Infections']}, 'descriptionModule': {'briefSummary': 'This study will evaluate the ecological impact on the intestinal microbiota and compare the safety and efficacy of temocillin compared to cefotaxime, in empiric treatment of febrile UTI. Half of participants will receive temocillin and the other half will receive cefotaxime.', 'detailedDescription': 'Temocillin is a narrow spectrum antibiotic with activity against gram negative bacteria inclusive many ESBL producing bacteria. Temocillin is approved and marketed in a few European countries since the 1980´s but not in Sweden.\n\nThe aim of the study is to find an ecological favorable alternative to cephalosporins in the treatment of this common indication.\n\nThe hypothesis is that treatment with temocillin causes less disturbances on the intestinal microbiota while at least comparable efficacy.\n\nThe study will be performed as an open prospective multicentre study with two parallel groups comparing 2 g temocillin three times daily with 1-2 g cefotaxim three times daily for 7-10 days in male and female adult patients with febrile urinary tract infection.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Males and females ≥ 18 years of age with suspected or confirmed febrile UTI, fulfilling at least one of the following signs and symptoms:\n\n * Flank pain or suprapubic pain, Tenderness over the kidney on physical examination, Urinary symptoms such as dysuria, urinary frequency or urinary urgency\n* Fever ≥ 38.0°C (highest temperature recorded at home or at the hospital)\n* Positive urinalysis tests (U-Nitrit and/or U-LPK)\n* Have a pre-treatment baseline urinary culture obtained\n* Require iv antibacterial treatment of the presumed infection\n* Fertile women: Agree to practice highly effective anti-contraceptive methods from study-start to TOC\n* Signed informed consent\n\nExclusion Criteria:\n\n* Have a documented history of hypersensitivity or allergic reaction to any beta-lactam\n* Pregnant or nursing women\n* Receipt of any prior potentially therapeutic antibacterial agent within 1 month before randomisation and sampling for urine and faecal cultures. Exceptions will prior treatment with pivmecillinam or nitrofurantoin.\n* Known chronic renal insufficiency (creatinine clearance \\< 10 mL/min at screening as estimated by Cockcroft-Gault), or receiving intermittent haemodialysis or peritoneal dialysis\n* Known colonization with ESBL\n* Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the subject or the quality of study data.'}, 'identificationModule': {'nctId': 'NCT02959957', 'briefTitle': 'Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Public Health Agency of Sweden'}, 'officialTitle': 'A Randomized, Controlled, Multicentre Trial of Collateral Damage on the Intestinal Microbiota Inferred by Temocillin Versus Cefotaxime in Patients Receiving Empirical Treatment for Febrile Urinary Tract Infections', 'orgStudyIdInfo': {'id': 'FoHM/UVI 2015'}, 'secondaryIdInfos': [{'id': '2015-003898-15', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Temocillin', 'description': 'Temocillin powder for solution för injection/infusion, per day 6 g (2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.', 'interventionNames': ['Drug: Temocillin']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Cefotaxime', 'description': 'Cefotaxime powder for solution för injection/infusion, per day 3-6 g (1-2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.', 'interventionNames': ['Drug: Cefotaxime']}], 'interventions': [{'name': 'Temocillin', 'type': 'DRUG', 'otherNames': ['Negaban'], 'description': 'Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial temocillin administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.', 'armGroupLabels': ['Temocillin']}, {'name': 'Cefotaxime', 'type': 'DRUG', 'otherNames': ['Claforan'], 'description': 'Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial cefotaxime administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.', 'armGroupLabels': ['Cefotaxime']}]}, 'contactsLocationsModule': {'locations': [{'zip': '171 76', 'city': 'Solna', 'state': 'Stockholm County', 'country': 'Sweden', 'facility': 'Karolinska University Hospital', 'geoPoint': {'lat': 59.36004, 'lon': 18.00086}}, {'zip': '251 87', 'city': 'Helsingborg', 'country': 'Sweden', 'facility': 'Helsingborg Hospital', 'geoPoint': {'lat': 56.04673, 'lon': 12.69437}}, {'zip': '291 85', 'city': 'Kristianstad', 'country': 'Sweden', 'facility': 'Centralsjukhuset Kristianstad', 'geoPoint': {'lat': 56.03129, 'lon': 14.15242}}, {'zip': '581 85', 'city': 'Linköping', 'country': 'Sweden', 'facility': 'Linköping University Hospital', 'geoPoint': {'lat': 58.41086, 'lon': 15.62157}}, {'zip': '221 85', 'city': 'Lund', 'country': 'Sweden', 'facility': 'Skåne University Hospital', 'geoPoint': {'lat': 55.70584, 'lon': 13.19321}}, {'zip': '601 82', 'city': 'Norrköping', 'country': 'Sweden', 'facility': 'Vrinnevisjukhuset i Norrköping', 'geoPoint': {'lat': 58.59419, 'lon': 16.1826}}, {'zip': '701 85', 'city': 'Örebro', 'country': 'Sweden', 'facility': 'Örebro University Hospital', 'geoPoint': {'lat': 59.27412, 'lon': 15.2066}}, {'zip': '83131', 'city': 'Östersund', 'country': 'Sweden', 'facility': 'Östersund Hospital', 'geoPoint': {'lat': 63.1792, 'lon': 14.63566}}, {'zip': '112 81', 'city': 'Stockholm', 'country': 'Sweden', 'facility': 'Capio S:t Görans hospital', 'geoPoint': {'lat': 59.32938, 'lon': 18.06871}}, {'zip': '856 43', 'city': 'Sundsvall', 'country': 'Sweden', 'facility': 'Sundsvall Hospital', 'geoPoint': {'lat': 62.39129, 'lon': 17.3063}}, {'zip': '901 85', 'city': 'Umeå', 'country': 'Sweden', 'facility': 'University Hospital of Umeå', 'geoPoint': {'lat': 63.82842, 'lon': 20.25972}}, {'zip': '721 89', 'city': 'Västerås', 'country': 'Sweden', 'facility': 'Västmanlands sjukhus i Västerås', 'geoPoint': {'lat': 59.61617, 'lon': 16.55276}}], 'overallOfficials': [{'name': 'Håkan Hanberger, Professor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University Hospital, Linkoeping'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Håkan Hanberger', 'class': 'OTHER_GOV'}, 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Professor', 'investigatorFullName': 'Håkan Hanberger', 'investigatorAffiliation': 'Public Health Agency of Sweden'}}}, 'annotationSection': {'annotationModule': {'unpostedAnnotation': {'unpostedEvents': [{'date': '2021-05-11', 'type': 'RELEASE'}, {'date': '2021-06-04', 'type': 'RESET'}], 'unpostedResponsibleParty': 'Håkan Hanberger, Professor, Linkoeping University'}}}}